HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses

Cristina Scielzo, Paolo Ghia, Antonio Conti, Angela Bachi, Giuseppe Guida, Massimo Geuna, Massimo Alessio, Federico Caligaris-Cappio

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL). We investigated 14 patients who were completely concordant for IgVH mutational status (unmutated vs. mutated), CD38 expression (positive vs. negative), and clinical behavior (progressive vs. stable); these patients were characterized as having either poor or good prognoses. The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HSl). In patients with poor prognoses, most HS1 protein was constitutively phosphorylated, whereas only a fraction was phosphorylated in patients with good prognoses. This difference was investigated in a larger cohort of 26 unselected patients. The survival curve of all 40 patients analyzed revealed that patients with predominately phosphorylated HS1 experience a significantly shorter median survival time. As HS1 is a protein pivotal in the signal cascade triggered by B cell receptor (BCR) stimulation, we studied its pattern of expression following BCR engagement. Normal mature B cells stimulated by anti-IgM shifted the non- or less-phosphorylated form of HS1 toward the more phosphorylated form. Naive B cells showed both HS1 forms while memory B cells expressed mainly the phosphorylated fraction. These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease.

Original languageEnglish
Pages (from-to)1644-1650
Number of pages7
JournalJournal of Clinical Investigation
Volume115
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Proteins
Survival
Proteomics
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. / Scielzo, Cristina; Ghia, Paolo; Conti, Antonio; Bachi, Angela; Guida, Giuseppe; Geuna, Massimo; Alessio, Massimo; Caligaris-Cappio, Federico.

In: Journal of Clinical Investigation, Vol. 115, No. 6, 06.2005, p. 1644-1650.

Research output: Contribution to journalArticle

Scielzo, Cristina ; Ghia, Paolo ; Conti, Antonio ; Bachi, Angela ; Guida, Giuseppe ; Geuna, Massimo ; Alessio, Massimo ; Caligaris-Cappio, Federico. / HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. In: Journal of Clinical Investigation. 2005 ; Vol. 115, No. 6. pp. 1644-1650.
@article{c6f8452a0cf546f890d841079e99467c,
title = "HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses",
abstract = "We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL). We investigated 14 patients who were completely concordant for IgVH mutational status (unmutated vs. mutated), CD38 expression (positive vs. negative), and clinical behavior (progressive vs. stable); these patients were characterized as having either poor or good prognoses. The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HSl). In patients with poor prognoses, most HS1 protein was constitutively phosphorylated, whereas only a fraction was phosphorylated in patients with good prognoses. This difference was investigated in a larger cohort of 26 unselected patients. The survival curve of all 40 patients analyzed revealed that patients with predominately phosphorylated HS1 experience a significantly shorter median survival time. As HS1 is a protein pivotal in the signal cascade triggered by B cell receptor (BCR) stimulation, we studied its pattern of expression following BCR engagement. Normal mature B cells stimulated by anti-IgM shifted the non- or less-phosphorylated form of HS1 toward the more phosphorylated form. Naive B cells showed both HS1 forms while memory B cells expressed mainly the phosphorylated fraction. These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease.",
author = "Cristina Scielzo and Paolo Ghia and Antonio Conti and Angela Bachi and Giuseppe Guida and Massimo Geuna and Massimo Alessio and Federico Caligaris-Cappio",
year = "2005",
month = "6",
doi = "10.1172/JCI24276",
language = "English",
volume = "115",
pages = "1644--1650",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses

AU - Scielzo, Cristina

AU - Ghia, Paolo

AU - Conti, Antonio

AU - Bachi, Angela

AU - Guida, Giuseppe

AU - Geuna, Massimo

AU - Alessio, Massimo

AU - Caligaris-Cappio, Federico

PY - 2005/6

Y1 - 2005/6

N2 - We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL). We investigated 14 patients who were completely concordant for IgVH mutational status (unmutated vs. mutated), CD38 expression (positive vs. negative), and clinical behavior (progressive vs. stable); these patients were characterized as having either poor or good prognoses. The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HSl). In patients with poor prognoses, most HS1 protein was constitutively phosphorylated, whereas only a fraction was phosphorylated in patients with good prognoses. This difference was investigated in a larger cohort of 26 unselected patients. The survival curve of all 40 patients analyzed revealed that patients with predominately phosphorylated HS1 experience a significantly shorter median survival time. As HS1 is a protein pivotal in the signal cascade triggered by B cell receptor (BCR) stimulation, we studied its pattern of expression following BCR engagement. Normal mature B cells stimulated by anti-IgM shifted the non- or less-phosphorylated form of HS1 toward the more phosphorylated form. Naive B cells showed both HS1 forms while memory B cells expressed mainly the phosphorylated fraction. These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease.

AB - We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL). We investigated 14 patients who were completely concordant for IgVH mutational status (unmutated vs. mutated), CD38 expression (positive vs. negative), and clinical behavior (progressive vs. stable); these patients were characterized as having either poor or good prognoses. The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HSl). In patients with poor prognoses, most HS1 protein was constitutively phosphorylated, whereas only a fraction was phosphorylated in patients with good prognoses. This difference was investigated in a larger cohort of 26 unselected patients. The survival curve of all 40 patients analyzed revealed that patients with predominately phosphorylated HS1 experience a significantly shorter median survival time. As HS1 is a protein pivotal in the signal cascade triggered by B cell receptor (BCR) stimulation, we studied its pattern of expression following BCR engagement. Normal mature B cells stimulated by anti-IgM shifted the non- or less-phosphorylated form of HS1 toward the more phosphorylated form. Naive B cells showed both HS1 forms while memory B cells expressed mainly the phosphorylated fraction. These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease.

UR - http://www.scopus.com/inward/record.url?scp=20444447080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444447080&partnerID=8YFLogxK

U2 - 10.1172/JCI24276

DO - 10.1172/JCI24276

M3 - Article

VL - 115

SP - 1644

EP - 1650

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -